dolutegravir
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infection, Human Immunodeficiency Virus
Conditions
Infection, Human Immunodeficiency Virus
Trial Timeline
May 1, 2011 → May 1, 2015
NCT ID
NCT01328041About dolutegravir
dolutegravir is a phase 3 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT01328041. Target conditions include Infection, Human Immunodeficiency Virus.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01499199 | Phase 3 | Completed |
| NCT01328041 | Phase 3 | Completed |
Competing Products
20 competing products in Infection, Human Immunodeficiency Virus